Eslam, Mohammed and Newsome, Philip N. and Sarin, Shiv K. and Anstee, Quentin M. and Targher, Giovanni and Romero-Gomez, Manuel and Zelber-Sagi, Shira and Wong, Vincent Wai-Sun and Dufour, Jean-Francois and Schattenberg, Joern M. and Kawaguchi, Takumi and Arrese, Marco and Valenti, Luca and Shiha, Gamal and Tiribelli, Claudio and Yki-Jarvinen, Hannele and Fan, Jian-Gao and Gronbaek, Henning and Yilmaz, Yusuf and Cortez-Pinto, Helena and Oliveira, Claudia P. and Bedossa, Pierre and Adams, Leon A. and Zheng, Ming-Hua and Fouad, Yasser and Chan, Wah-Kheong and Mendez-Sanchez, Nahum and Ahn, Sang Hoon and Castera, Laurent and Bugianesi, Elisabetta and Ratziu, Vlad and George, Jacob (2020) A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. Journal of Hepatology, 73 (1). pp. 202-209. ISSN 0168-8278, DOI https://doi.org/10.1016/j.jhep.2020.03.039.
Full text not available from this repository.Abstract
The exclusion of other chronic liver diseases including ``excess'' alcohol intake has until now been necessary to establish a diagnosis of metabolic dysfunction-associated fatty liver disease (MAFLD). However, given our current understanding of the pathogenesis of MAFLD and its rising prevalence, ``positive criteria'' to diagnose the disease are required. In this work, a panel of international experts from 22 countries propose a new definition for the diagnosis of MAFLD that is both comprehensive and simple, and is independent of other liver diseases. The criteria are based on evidence of hepatic steatosis, in addition to one of the following three criteria, namely overweight/obesity, presence of type 2 diabetes mellitus, or evidence of metabolic dysregulation. We propose that disease assessment and stratification of severity should extend beyond a simple dichotomous classification to steatohepatitis vs. non-steatohepatitis. The group also suggests a set of criteria to define MAFLD-associated cirrhosis and proposes a conceptual framework to consider other causes of fatty liver disease. Finally, we bring clarity to the distinction between diagnostic criteria and inclusion criteria for research studies and clinical trials. Reaching consensus on the criteria for MAFLD will help unify the terminology (e.g. for ICD-coding), enhance the legitimacy of clinical practice and clinical trials, improve clinical care and move the clinical and scientific field of liver research forward. (C) 2020 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
| Item Type: | Article |
|---|---|
| Funders: | Robert W. Storr Bequest, Sydney Medical Foundation, University Hospitals Birmingham NHS Foundation Trust, National Health and Medical Research Council [Grant No: APP1053206, APP1107178, APP1108422, APP1149976], National Health and Medical Research Council |
| Uncontrolled Keywords: | MAFLD; Cirrhosis; Diagnostic criteria; Metabolic; NAFLD; Steatohepatitis; Diabetes; Obesity |
| Subjects: | R Medicine > R Medicine (General) R Medicine > RC Internal medicine |
| Divisions: | Faculty of Medicine |
| Depositing User: | Ms Zaharah Ramly |
| Date Deposited: | 30 Oct 2024 02:12 |
| Last Modified: | 30 Oct 2024 02:12 |
| URI: | http://eprints.um.edu.my/id/eprint/36571 |
Actions (login required)
 |
View Item |
